Related Experiment Video
Updated: Jul 17, 2026
03:23
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Chronic eosinophilic pneumonia: a review.
Mahmood Alam1, Nausherwan K Burki
1Division of Pulmonary Medicine, MC 1225, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1321, USA.
Southern Medical Journal
|February 3, 2007
Summary
Chronic eosinophilic pneumonia (CEP) involves lung eosinophil accumulation. Oral steroids effectively treat CEP symptoms, but relapses are common upon dose reduction or treatment cessation.
Area of Science:
- Pulmonology
- Immunology
Background:
- Chronic eosinophilic pneumonia (CEP) is a rare lung disease characterized by eosinophil infiltration.
- The exact cause is unknown, but Th2 lymphocyte-derived chemoattractants like eotaxin, RANTES, and IL-5 are implicated.
- CEP typically affects middle-aged women and presents insidiously with respiratory symptoms and constitutional signs.
Purpose of the Study:
- To summarize the key features, diagnosis, and treatment of Chronic Eosinophilic Pneumonia.
- To highlight the role of eosinophils and associated cytokines in CEP pathogenesis.
- To discuss the efficacy and relapse patterns associated with standard corticosteroid therapy.
Main Methods:
- Review of existing literature on Chronic Eosinophilic Pneumonia.
- Analysis of clinical presentation, radiographic findings, and laboratory results.
- Evaluation of treatment responses and relapse rates with oral and inhaled corticosteroids.
Main Results:
- CEP diagnosis is supported by peripheral eosinophilia and characteristic bilateral peripheral lung opacities on chest imaging.
- Oral corticosteroids provide rapid symptom and radiographic improvement in most patients.
- High relapse rates (>80%) are observed after treatment cessation or significant dose reduction.
Conclusions:
- Chronic eosinophilic pneumonia requires prolonged treatment, often with oral steroids, due to frequent relapses.
- Inhaled corticosteroids may offer a potential adjunctive or alternative treatment strategy.
- Further research into CEP pathogenesis and long-term management is warranted.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...